Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice

Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice Objectives To investigate the pathologic changes and pathogenesis of multikinase inhibitor (MKI)-induced skin lesions in an animal model. Methods Tumor-bearing nude mice and BDF1 mice were treated with different doses (30–240 mg/kg, Bid) of sorafenib. The pathology and severity of the skin lesions was assessed and evaluated. The concentration of sorafenib in the skin was also determined. Results Sorafenib transiently induced skin rash at high doses (120–240 mg/kg). The induced skin lesions had pathological manifestations resembling the observations in human patients. The skin of mice treated with sorafenib had significantly increased pathological scores and thickness of the stratum spinosum compared with the control, and induced more severe cutaneous lesions in nude mice than in BDF1 mice. The severity of skin lesions was correlated with the local concentration of sorafenib in the skin, which was significantly higher in nude mice than in BDF1 mice. Sorafenib treatment significantly increased the expression of F4-80, Ly6G, tumor growth factor (TGF)-1β, Smad2/3, α-smooth-muscle actin, and proliferat- ing cell nuclear antigen. Conclusions The severity of skin lesions was positively correlated with the concentration of sorafenib in the skin. Our results suggested the involvement of the TGF-β1/Smads signaling pathway in the skin reaction induced by MKIs. Keywords Multikinase http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice

Download PDF
9 pages
Read Article

Loading next page...
 
/lp/springer_journal/multikinase-inhibitor-sorafenib-induces-skin-toxicities-in-tumor-S7VBlO6naz
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
DOI
10.1007/s00280-018-3575-y
Publisher site
See Article on Publisher Site

Abstract

Objectives To investigate the pathologic changes and pathogenesis of multikinase inhibitor (MKI)-induced skin lesions in an animal model. Methods Tumor-bearing nude mice and BDF1 mice were treated with different doses (30–240 mg/kg, Bid) of sorafenib. The pathology and severity of the skin lesions was assessed and evaluated. The concentration of sorafenib in the skin was also determined. Results Sorafenib transiently induced skin rash at high doses (120–240 mg/kg). The induced skin lesions had pathological manifestations resembling the observations in human patients. The skin of mice treated with sorafenib had significantly increased pathological scores and thickness of the stratum spinosum compared with the control, and induced more severe cutaneous lesions in nude mice than in BDF1 mice. The severity of skin lesions was correlated with the local concentration of sorafenib in the skin, which was significantly higher in nude mice than in BDF1 mice. Sorafenib treatment significantly increased the expression of F4-80, Ly6G, tumor growth factor (TGF)-1β, Smad2/3, α-smooth-muscle actin, and proliferat- ing cell nuclear antigen. Conclusions The severity of skin lesions was positively correlated with the concentration of sorafenib in the skin. Our results suggested the involvement of the TGF-β1/Smads signaling pathway in the skin reaction induced by MKIs. Keywords Multikinase

Journal

Cancer Chemotherapy and Pharmacology – Springer Journals

Published: Apr 9, 2018

References

  • Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management
    Chanprapaph, K; Rutnin, S; Vachiramon, V
  • Novel molecular-targeted therapeutics for the treatment of cancer
    Yasui, H; Imai, K
  • Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature
    Massey, PR; Okman, JS; Wilkerson, J; Cowen, EW
  • Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
    Abdel-Rahman, O; Lamarca, A
  • Kinase inhibitors in the treatment of immune-mediated disease
    Kontzias, A; Laurence, A; Gadina, M; O’Shea, JJ
  • Advances in the management of cutaneous toxicities of targeted therapies
    Robert, C; Sibaud, V; Mateus, C; Cherpelis, BS
  • Understanding, recognizing, and managing toxicities of targeted anticancer therapies
    Dy, GK; Adjei, AA
  • Skin toxicity of anti-cancer therapy
    Ulrich, J; Hartmann, JT; Dorr, W; Ugurel, S
  • Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib
    Lacouture, ME; Wu, S; Robert, C
  • Hand-foot skin reaction in patients treated with sorafenib:a clinicopathological study ofcutaneous manifestations dueto multitargeted kinase inhibitor therapy
    Yang, CH; Lin, WC; Chuang, CK; Chang, YC; Pang, ST; Lin, YC
  • Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib
    Lipworth, AD; Robert, C; Zhu, AX
  • Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma
    Ikeda, M; Fujita, T; Mii, S; Tanabe, K; Tabata, K; Matsumoto, K; Satoh, T; Iwamura, M
  • Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor
    Autier, J; Escudier, B; Wechsler, J; Spatz, A; Robert, C
  • Cutaneous side effects of new antitumor drugs: clinical features and management
    Gutzmer, R; Wollenberg, A; Ugurel, S; Homey, B; Ganser, A; Kapp, A
  • Effects of sorafenib dose on acquired reversible resistance and toxicity in hepatocellular carcinoma
    Kuczynski, EA; Lee, CR; Man, S; Chen, E; Kerbel, RS
  • Effect of FGF10 monoclonal antibody on psoriasis-like model in guinea pigs
    Xia, JX; Mei, XL; Zhu, WJ; Li, X; Jin, XH; Mou, Y; Yu, K; Wang, YY; Li, FQ
  • Is epidermal cell proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines?
    Baker, BS; Brent, L; Valdimarsson, H; Powles, AV; al-Imara, L; Walker, M; Fry, L
  • Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite
    Sparidans, RW; Vlaming, ML; Lagas, JS; Schinkel, AH; Schellens, JH; Beijnen, JH
  • Signalling by transforming growth factor beta isoforms in wound healing and tissue regeneration
    Gilbert, RW; Vickaryous, MK; Viloria-Petit, AM
  • Hand-foot and stump syndrome to sorafenib
    Lai, SE; Kuzel, T; Lacouture, ME
  • Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3)
    Yamamoto, K; Mizumoto, A; Nishimura, K
  • Prostaglandin E1 reduces the keratinocyte toxicity of sorafenib by maintaining signal transducer and activator of transcription 3 (STAT3) activity and enhancing the cAMP response element binding protein (CREB) activity
    Shichiri, H; Yamamoto, K; Tokura, M